How would you manage a patient with metastatic hormone sensitive prostate cancer who received docetaxel but has toxicity while on darolutamide (+ leuprolide)??  

Darolutamide is generally considered the best-tolerated among the new hormonal agents. In this situation, which alternative NHA would you consider switching to – enzalutamide or apalutamide?

If patient's PSA is undetectable, would you consider just treating with ADT alone?